LH: What Your Number Changes About Your Treatment

What LH Actually Measures

Luteinizing hormone is a gonadotropin produced by the anterior pituitary gland. It travels through the bloodstream to the testes or ovaries, where it stimulates sex hormone production and supports gametogenesis. In men, LH binds to Leydig cell receptors and drives testosterone synthesis [1]. In women, the midcycle LH surge triggers ovulation and supports the corpus luteum during the early luteal phase [2].

A single LH value, drawn alongside testosterone (men) or estradiol and FSH (women), creates a diagnostic fork. The 2018 Endocrine Society Clinical Practice Guideline for testosterone therapy in men with hypogonadism states that "measurement of serum LH and FSH levels can distinguish primary (hypergonadotropic) from secondary (hypogonadotropic) hypogonadism" [3]. That fork determines whether a patient receives testosterone replacement, a selective estrogen receptor modulator like clomiphene, or a referral to endocrinology or reproductive medicine.

Blood draws should occur between 8:00 and 10:00 AM, when the hypothalamic-pituitary-gonadal (HPG) axis is most active. LH is secreted in pulses. A single measurement can miss a trough or catch a peak, so clinicians sometimes order two morning draws on separate days before making treatment changes [3].

How High LH Redirects Your Treatment

An LH above the reference range paired with low testosterone (<300 ng/dL) confirms primary hypogonadism. The testes are not responding adequately to gonadotropin stimulation, and the pituitary compensates by releasing more LH. This pattern appears in Klinefelter syndrome (47,XXY), testicular injury, orchitis, and age-related Leydig cell decline [4].

Treatment here is straightforward. Testosterone replacement therapy (TRT), whether cypionate, enanthate, or a topical gel, is the standard of care. The pituitary is already working overtime. Prescribing a SERM like clomiphene to raise LH further would be counterproductive since the bottleneck is gonadal output, not gonadotropin drive.

For women, elevated LH combined with elevated FSH and low estradiol is the biochemical signature of primary ovarian insufficiency (POI) or menopause. The 2022 Hormone Therapy Position Statement from The North American Menopause Society (NAMS) recommends hormone therapy for symptomatic women under 60 or within 10 years of menopause onset, particularly those with POI, where early estrogen replacement protects bone density and cardiovascular health [5]. In a prospective cohort of 1,014 women with POI, those who received estrogen-progestogen therapy had a 50% lower fracture risk compared to untreated controls over 10 years of follow-up [6].

How Low or Suppressed LH Changes the Clinical Plan

Low LH with low testosterone defines secondary (hypogonadotropic) hypogonadism. The problem sits upstream. Causes include pituitary adenomas, hyperprolactinemia, chronic opioid use, obesity, obstructive sleep apnea, and anabolic steroid abuse [3]. Before prescribing any hormone therapy, clinicians should order a prolactin level and consider pituitary MRI to rule out structural lesions.

Drug choice pivots on fertility goals. Men who want to preserve or restore spermatogenesis should avoid exogenous testosterone, which suppresses both LH and FSH to near-zero and can render a man azoospermic within 3 to 6 months [7]. The Endocrine Society advises that "testosterone therapy should not be initiated in men desiring fertility in the near term" [3].

Alternatives for these patients include:

• Clomiphene citrate (25 to 50 mg daily or every other day, off-label): blocks hypothalamic estrogen receptors, disinhibiting GnRH pulses and raising LH and FSH. A retrospective study of 400 hypogonadal men treated with clomiphene at a single academic center found a mean testosterone increase from 228 ng/dL to 612 ng/dL after 3 months, with sperm counts maintained or improved in 85% of subjects [8].
• Enclomiphene (the trans-isomer of clomiphene): acts with similar mechanism but fewer estrogenic side effects. Not yet FDA-approved as of May 2026, though clinical trials have shown comparable LH and testosterone responses [9].
• Human chorionic gonadotropin (hCG) (1,000 to 3 to 000 IU subcutaneously two to three times per week): mimics LH at the Leydig cell receptor and supports intratesticular testosterone, preserving spermatogenesis while raising serum testosterone [10].

For women with hypogonadotropic hypogonadism (as seen in functional hypothalamic amenorrhea from energy deficit, stress, or excessive exercise), treatment targets the root cause first. Weight restoration and stress management often restore pulsatile GnRH secretion. If fertility is desired and the axis does not recover, gonadotropin injections (exogenous LH and FSH) or pulsatile GnRH pump therapy can induce ovulation [11].

LH on TRT: Why It Drops and What That Means

Exogenous testosterone provides negative feedback to the hypothalamus and pituitary, suppressing GnRH, LH, and FSH. Within 2 to 4 weeks of starting injectable testosterone cypionate at standard replacement doses (100 to 200 mg weekly), LH typically falls below 1.0 IU/L. At 12 weeks, most men on TRT show LH values <0.5 IU/L [7].

This suppression is expected and is not a side effect. Clinicians use the suppressed LH as a compliance marker. If a patient on TRT still shows LH in the normal or elevated range, adherence should be questioned, the injection technique reviewed, or the testosterone preparation verified.

The clinical problem arises when a man on TRT wants to conceive. Spermatogenesis requires intratesticular testosterone concentrations 50 to 100 times higher than serum levels, and this local production depends on LH stimulation of Leydig cells [12]. Exogenous testosterone floods serum but leaves intratesticular levels insufficient for sperm production.

Recovery after TRT discontinuation varies. A 2021 meta-analysis examining HPG axis recovery after exogenous testosterone use found that 67% of men recovered sperm in the ejaculate by 6 months and 90% by 12 months, though baseline sperm parameters were not always restored [13]. Clinicians often bridge with hCG or clomiphene during the recovery window.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and a lead author on Endocrine Society hypogonadism guidelines, has noted: "The suppressive effect of testosterone on the HPG axis is predictable and dose-dependent. Recovery is the rule, but the timeline is variable, and patients should be counseled before starting therapy" [3].

LH in Women: Fertility Timing, PCOS, and Menopause Transitions

The LH-to-FSH ratio carries diagnostic weight in reproductive endocrinology. In polycystic ovary syndrome (PCOS), LH is often elevated relative to FSH, with an LH:FSH ratio exceeding 2:1 in classic presentations. The 2023 International Evidence-Based Guideline for the Assessment and Management of PCOS recommends that while the LH:FSH ratio is no longer required for diagnosis, it "remains a supportive biochemical feature" when present [14].

A 2004 meta-analysis in Human Reproduction found that a midcycle LH surge above 40 IU/L predicted ovulation within 24 to 36 hours with 98% specificity, forming the basis for ovulation predictor kits (OPKs) used at home [2]. However, certain conditions produce misleading LH patterns. Women with hypothalamic amenorrhea show persistently low LH (<2 IU/L), confirming central suppression. Women in perimenopause may see erratic LH spikes that do not reliably predict ovulation, making OPKs less useful during the transition years.

During menopause confirmation, a persistently elevated LH (above 25 IU/L) alongside FSH above 30 IU/L and undetectable estradiol confirms the ovary is no longer responsive. This pattern supports the decision to initiate systemic estrogen therapy for vasomotor symptoms, with the NAMS position statement recommending the "lowest effective dose for the shortest duration consistent with treatment goals" [5]. For women with an intact uterus, a progestogen must be added to prevent endometrial hyperplasia.

LH Testing Frequency and Treatment Adjustment Protocols

Once a diagnosis is established, the frequency of LH monitoring depends on the treatment pathway. For men on TRT, the Endocrine Society recommends checking testosterone 3 to 6 months after initiation and then annually, with LH measured only if there is a clinical reason (compliance question, considering fertility, or evaluating for recovery) [3].

For men on clomiphene, LH monitoring is more frequent. Baseline LH is drawn before starting, then repeated at 4 to 6 weeks and 12 weeks. An LH that exceeds 15 IU/L on clomiphene without proportional testosterone rise suggests that the testes may have limited reserve, and the clinician should consider transitioning to TRT rather than escalating the SERM dose [8].

For women undergoing ovulation induction with gonadotropins, LH is monitored alongside estradiol and transvaginal ultrasound every 1 to 3 days during the stimulation phase. The goal is to trigger the final oocyte maturation (via hCG or a GnRH agonist trigger) when follicles reach 17 to 18 mm and estradiol levels are consistent with the follicle count [11].

The American Association of Clinical Endocrinologists (AACE) 2024 guidelines for hypogonadism management reinforce that "isolated LH measurement without concurrent sex steroid assessment has limited diagnostic value" [15]. The two labs should always be interpreted as a pair.

When LH Indicates Something Beyond Hormone Therapy

Not every abnormal LH result leads to testosterone or estrogen prescriptions. Certain patterns demand further workup before any hormonal intervention.

A very low LH (<0.5 IU/L) in a man not on exogenous androgens raises suspicion for a pituitary mass. Prolactinomas, the most common pituitary adenomas, suppress GnRH pulsatility and lower LH. Serum prolactin above 200 ng/mL strongly suggests a macroprolactinoma, and MRI of the sella turcica is indicated [16]. Treatment is typically a dopamine agonist (cabergoline 0.25 to 1 mg twice weekly), not testosterone. As the prolactinoma shrinks and prolactin normalizes, LH often recovers, and testosterone rises without replacement.

Chronic opioid use is another common cause of suppressed LH. A cross-sectional analysis of 11,327 men on long-term opioids found that 53% had total testosterone below 300 ng/dL, with mean LH values 40% lower than age-matched controls not using opioids [17]. Opioid-induced androgen deficiency (OIAD) is best managed by reducing or tapering the opioid when possible, with testosterone replacement reserved for cases where pain management cannot be altered.

In adolescent males with delayed puberty, an LH below 0.3 IU/L after age 14 differentiates constitutional delay from isolated hypogonadotropic hypogonadism (IHH), including Kallmann syndrome. A GnRH stimulation test can help distinguish the two. IHH may require lifelong gonadotropin therapy or pulsatile GnRH to achieve both virilization and fertility [18].

How to Raise or Lower LH Without Medication

Lifestyle factors influence LH secretion in measurable ways. Obesity suppresses LH amplitude and frequency through aromatase-mediated conversion of testosterone to estradiol, which feeds back on the hypothalamus. A prospective trial of 891 men with BMI above 30 found that a 10% reduction in body weight over 12 months was associated with a 25% increase in LH pulsatility and a mean testosterone rise of 84 ng/dL, without any pharmacologic intervention [19].

Sleep deprivation also blunts LH. A study restricting healthy young men to 5 hours of sleep per night for one week demonstrated a 10 to 15% decline in morning testosterone, with corresponding reductions in LH pulse amplitude measured by frequent blood sampling [20]. Restoring 7 to 9 hours of nightly sleep normalized the axis within days.

For women with functional hypothalamic amenorrhea, energy availability is the dominant modulator. When caloric intake falls below approximately 30 kcal per kilogram of fat-free mass per day, the hypothalamus downregulates GnRH pulses and LH drops. The Endocrine Society guideline on functional hypothalamic amenorrhea recommends nutritional rehabilitation as first-line therapy, with a target of positive energy balance for at least 3 to 6 months before considering pharmacologic ovulation induction [21].

Zinc supplementation (30 mg elemental zinc daily) has shown modest LH-supportive effects in zinc-deficient populations, but supplementation in zinc-replete individuals does not meaningfully alter LH [22].